Professional Documents
Culture Documents
com)
Home > April 2010 Vol. 2 Issue 4 > L-Carnosine's Effects on Cataract Development
Abstract
Cataracts are the leading cause of blindness worldwide. With an aging population, the
incidence and prevalence of cataract-induced blindness is expected to rise
considerably. L-carnosine (β-alanyl-L-histidine) is an endogenous dipeptide compound
in vertebrates that has been designated an “antiaging” molecule due to its ability to
delay senescence of cells. L-carnosine and N-acetyl-L-carnosine have demonstrated a
reduction in opacification of the lens when used as a direct instillation to the eye. These
compounds represent a promising new means of addressing cataracts.
Introduction
Cataract is the opacification of the ocular lens or capsule. According to the World
Health Organization, in the year 2002, the last year that statistics were estimated,
cataracts caused nearly half of the 37 million cases of blindness worldwide.1 In the
United States, 20.5 million Americans over the age of 40 are affected in at least one
eye, with an estimated increase to over 30 million Americans by the year 2020.2
Surgery is the only treatment option available and, while highly successful at restoring
sight, it is not feasible in many developing countries that lack the infrastructure for
adequate access to care.3 Ultimately, an easily disseminated medication that is
economical and convenient could have a profound impact on the prevalence of the
disease.4 Currently no agent is approved for use in preventing or delaying the onset of
cataracts. There is evidence, however, that the natural agent L-carnosine (β-alanyl-L-
histidine) effectively delays cataract development. The uniformity of benefit from
preliminary evidence on carnosine and lens health, combined with a low toxicity profile
make this endogenous dipeptide an intriguing candidate for prevention of cataract
formation.
Background
Lens fiber cells are long, transparent cells continually produced by epithelial cells in the
anterior portion of the lens and growing around the periphery (like longitudinal lines on a
globe) to reach the posterior aspect. This process begins embryologically with the first
lens fiber cells essentially providing the nexus upon which fetal and then adult lens
fibers are built. Anatomically, these cells accumulate like layers in an onion, with the
center becoming the nuclear region, outside of which is the cortical region. Aptly
named, the subcapsular region is found between the cortical region and capsule that
encompasses the lens.
Of note, all mature lens fiber cells lack nuclei or organelles, necessitating diffusion of
many molecules, including nutrients, into the cells. The lack of intracellular structures
and complete solubility of proteins, predominantly proteins called crystallins, within the
lens cells is necessary for light rays to penetrate to the back of the eye.
Cataracts are classified into 3 types, depending on the region of the eye in
which they originate.
Cataracts are classified into 3 types, depending on the region of the eye in which they
originate. Nuclear cataracts begin at the center of the lens and affect distant vision in
particular. These are the most common type of cataract and are thought to occur due to
the aging process—thus the common term “age-related” or “senile” cataracts. Cortical
cataracts are also called “diabetic cataracts”; they begin in the periphery of the lens and
progress inward in a spoke-like fashion. Subcapsular cataracts usually begin at the
back of the lens (posterior subcapsular cataracts) and are found in patients with a
history of diabetes, steroid use, retinitis pigmentosa, or severe nearsightedness.
While symptomology varies between type and degree of cataract, the main symptoms
of cloudy vision and sensitivity to glare is common to all forms at some stage of
development. Double vision or multiple images in one eye can also occur. Unique to the
development of nuclear cataracts, there may be a period of “second sight,” when the
focus of near objects improves. This ability to see close objects more clearly is short
lived, however, as the lens becomes more opaque and cloudy vision more severe.
Cortical cataracts affect both distant and near vision and, while blurring occurs,
sensitivity to glare and loss of contrast are more significant in this type of cataract.
Subcapsular cataracts usually occur concomitantly with nuclear or cortical, and this type
is marked by a more rapid progression.
Before any agents, synthetic or natural, are considered it is prudent to address known
risk factors for cataract development. Risk factors include aging, diabetes, obesity,
exposure to UVB radiation, smoking, previous eye surgery, prolonged use of some
drugs (eg, corticosteroids, some diuretics, antipsychotics), and previous eye injury or
inflammation. While many of these can be actively addressed through lifestyle
modifications, others such as aging and eye injury clearly cannot be controlled. In
addition to these established risk factors, epidemiological data suggests dietary intake
of several nutrients can be protective. Nutrients such as taurine, carotenoiods,
tocopherol, and acsorbate have shown a protective role from the development of some
types of cataracts.5,6
The presence of endogenous carnosine in the lens of the eye suggests it is needed in
normal physiological processes.8 Of note, there is no evidence that the eye contains
carnosine synthase. Therefore carnosine, like many other nutrients, must be derived
from systemic circulation, diffusing into the aqueous humor then subsequently into the
lens cells themselves. Carnosinase, the enzyme that degrades carnosine into its
component amino acids, is found in the eye. The presence of carnosinase may result in
rapid degradation of carnosine into its component amino acids.
The ability of L-carnosine to attenuate the products of lipid peroxidation within the
ocular lens was first suggested by Dr. Alan Babizhayev and colleagues in 1987.10
Indeed, much research has since confirmed that carnosine reduces the formation of
lipid peroxides within the lens.11,12,13
Separately, carnosine has been shown to act as an alternative target for glycation, a
“sacrificial transglycation,” that effectively binds sugars to itself rendering them
unavailable to bind proteins. This leads to a measurable decrease in AGEs and may be
responsible for much of carnosine’s antisenescence action apart from its antioxidant
capacity.19
Remarkably, L-carnosine has been shown capable of deaggregating the crystalline lens
proteins that directly result in opacity. Methylglyoxal-induced glycation of α-crystallin
aggregates was reversed with the addition of carnosine to the media.21 The ability of
carnosine to denatured protein aggregates was also demonstrated in an in vitro study of
rat lenses. Both L- and D-carnosine had a “disassembling” effect on α-crystallin fibrils
and restored the transparency of cataractous lenses. This was accompanied by a
reduction in the average size of the proteins, confirming that disassembly did take
place.22
In Vivo Studies
In one study using rats with streptozocin-induced diabetes, cataract development was
shown to progress in a biphasic manner, with a slow progression in the first 8 weeks
followed by a rapid increase in the next 5 weeks. Carnosine delayed the onset of lens
opacification in the early stages of cataract development, reaching statistical
significance at week 4 (P<0.05), but failed to affect later progression of the disease.
This rodent study also demonstrated a reduction in the levels of AGEs in treated eyes
versus untreated, which was concordant with better preservation of glutathione and
catalase levels in the treated groups.27
NAC may not only act as a progdrug but may itself be involved in the antiaggregation
effects observed with NAC-containing eye drops. A rodent study using UV-induced
cataractogenesis supported this finding and suggested that a mixture of D-pantethine
and NAC is even more effective than NAC alone in its antiaggregate effects.28
A recent study using rats with streptozocin-induced diabetes showed a delay in the
development of cataracts using an instillation of aspirin (1%), L-carnosine (1%), or an
alternating combination of the 2. Both single agent interventions delayed cataracts while
the combination was more effective than either agent alone. In addition, there was an
increase in the levels of soluble protein in the lenses of the treated groups versus
controls.29
In a small study, 30 dogs of various breeds with existing lens opacities were
administered a combination product containing 2% NAC. Additional ingredients in the
proprietary formula include glutathione, cysteine ascorbate, L-taurine, and riboflavin
(Ocluvet™, by Practivet, Arizona, USA). 58 eyes of 30 dogs were evaluated, 22 with
mature cataract, 13 with immature cataract, 9 with cataract associated with eye
inflammation, and 14 with nuclear sclerosis. Images of the lenses were taken at weeks
2, 4, and 8. Objective measurement of lens opacification was determined by a lens
opacification index (LOI) using computerized integration of the grayscale level of each
pixel across the lens image. There was a reduction in the level of LOI in all groups,
although this was only statistically significant in the immature cataract and nuclear
sclerosis groups. Subjectively, owners perceived improvement in 80% of the dogs
studied. The greater benefit in early cataract development supports in vitro data that
suggests later stages of cataract development appear to overwhelm the benefits of
antioxidant support.30
Another canine study using 1.0% NAC in its patented formulation (Can-C®, Innovative
Vision Products, Delaware, USA) used 30 dogs in the treatment group, 15 dogs in
placebo-controlled group, and 10 dogs without treatment. All dogs had cataracts at the
start and all eyes were assessed. Placebo consisted of all ingredients in the drops
except NAC. After 6 months of treatment, 96% of eyes in the treatment group showed
improvement in the slit image and retroillumination photographs. No mention is given in
the publication of the statistical analysis or of the results of the 2 nontreatment
groups.31
Babizhayev and colleagues have shown beneficial effects of 1.0% NAC instillation in
the eyes in several small human clinical trials. In a randomized study of 49 subjects with
senile cataracts (76 affected eyes), 26 (41 affected eyes) were given NAC (1.0%)
eyedrops twice daily. There were 2 control groups: a placebo group of 13 patients (21
affected eyes) who received an eye drop formulation containing all ingredients but NAC
and an untreated group of 10 patients (14 eyes) who did not receive any eye drops. For
statistical analysis, the control groups were pooled. The 6-month outcome showed 90%
of patients in the treated group had improved visual acuity and 89% showed improved
glare sensitivity. Image analysis of the cataracts at 6 months showed a statistically
significant difference (P<.0001) using an in-house imaging that included slit-lamp
assessment and retroillumination of the lenes to assess.32
In a continuation of the above study, the participants were assessed every 6 months for
a total of 24 months. At 24 months no one in the treatment group had declining visual
acuity, while overall there was a decline in the control group. Overall, reductions in glare
sensitivity and visual acuity were sustained for the 24 month duration of the study; this
difference was statistically significant (P< .0001).33
In another trial by the same group, 65 older drivers with 1 or both eyes affected by
cataract and 72 older adult controls without cataract were recruited to participate in a
double-blind, placebo-controlled trial. Assessment of glare sensitivity (halos) at red and
green targets was made using an in-house test. At 4 months participants receiving NAC
had a statistically significant improvement in visual acuity and glare sensitivity
(P<0.001).34
In 2009 another trial of 75 patients with cataracts and 72 without, 1.0% NAC was
instilled daily for 9 months. In both groups visual acuity and reduction in glare sensitivity
reached statistical significance (P<0.001) at 9 months.35
Discussion
Conclusion
References
© 2020 Natural Medicine Journal (ISSN 2157-6769) | Terms & Conditions | Privacy
Policy | Contact Us
Links
[1] https://www.naturalmedicinejournal.com/journal/2010-04/l-carnosines-effects-cataract-development